Revenue Growth
Revenue increased by 10% year-over-year, reaching $14.7 million for Q3 2025, driven by growth in the U.S. heart failure business.
Expansion of Active Implanting Centers
The company added 10 net new centers in Q3, bringing the total to 250 active implanting centers in the U.S.
Gross Margin Improvement
Gross margin increased to 87% in Q3 2025, up from 83% in Q3 2024, due to increased average selling prices and improved manufacturing efficiencies.
Category I CPT Code Approval
Transition to a Category I CPT code effective January 1, 2026, expected to improve reimbursement and reduce prior authorization denials.
Positive Developments in Clinical Evidence
Increasing flow of independent peer-reviewed publications reporting positive patient outcomes and reduced hospitalizations with Barostim therapy.